These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19326383)

  • 1. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
    Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D
    ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of azaindole-alpha-alkyloxyphenylpropionic acid analogues as PPARalpha/gamma agonists.
    Cai Z; Feng J; Guo Y; Li P; Shen Z; Chu F; Guo Z
    Bioorg Med Chem; 2006 Feb; 14(3):866-74. PubMed ID: 16249089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
    Shi GQ; Dropinski JF; McKeever BM; Xu S; Becker JW; Berger JP; MacNaul KL; Elbrecht A; Zhou G; Doebber TW; Wang P; Chao YS; Forrest M; Heck JV; Moller DE; Jones AB
    J Med Chem; 2005 Jun; 48(13):4457-68. PubMed ID: 15974597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.
    Casimiro-Garcia A; Bigge CF; Davis JA; Padalino T; Pulaski J; Ohren JF; McConnell P; Kane CD; Royer LJ; Stevens KA; Auerbach BJ; Collard WT; McGregor C; Fakhoury SA; Schaum RP; Zhou H
    Bioorg Med Chem; 2008 May; 16(9):4883-907. PubMed ID: 18394907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
    Li Z; Liao C; Ko BC; Shan S; Tong EH; Yin Z; Pan D; Wong VK; Shi L; Ning ZQ; Hu W; Zhou J; Chung SS; Lu XP
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3507-11. PubMed ID: 15177462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
    Kim E; Park CS; Han T; Bae MH; Chong W; Lee CH; Shin YA; Ahn BN; Kim MK; Shin CY; Son MH; Kim JK; Moon HS; Shim HJ; Kim EJ; Kim SH; Lim JI; Lee CH
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4993-6. PubMed ID: 18771917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2009 May; 19(10):2683-7. PubMed ID: 19376700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
    Bénardeau A; Benz J; Binggeli A; Blum D; Boehringer M; Grether U; Hilpert H; Kuhn B; Märki HP; Meyer M; Püntener K; Raab S; Ruf A; Schlatter D; Mohr P
    Bioorg Med Chem Lett; 2009 May; 19(9):2468-73. PubMed ID: 19349176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
    Zhang H; Ryono DE; Devasthale P; Wang W; O'Malley K; Farrelly D; Gu L; Harrity T; Cap M; Chu C; Locke K; Zhang L; Lippy J; Kunselman L; Morgan N; Flynn N; Moore L; Hosagrahara V; Zhang L; Kadiyala P; Xu C; Doweyko AM; Bell A; Chang C; Muckelbauer J; Zahler R; Hariharan N; Cheng PT
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1451-6. PubMed ID: 19201606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
    Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
    J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.
    Xu Y; Rito CJ; Etgen GJ; Ardecky RJ; Bean JS; Bensch WR; Bosley JR; Broderick CL; Brooks DA; Dominianni SJ; Hahn PJ; Liu S; Mais DE; Montrose-Rafizadeh C; Ogilvie KM; Oldham BA; Peters M; Rungta DK; Shuker AJ; Stephenson GA; Tripp AE; Wilson SB; Winneroski LL; Zink R; Kauffman RF; McCarthy JR
    J Med Chem; 2004 May; 47(10):2422-5. PubMed ID: 15115385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
    Kuhn B; Hilpert H; Benz J; Binggeli A; Grether U; Humm R; Märki HP; Meyer M; Mohr P
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4016-20. PubMed ID: 16737814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of carbazole derivatives as PPAR alpha/gamma dual agonists and antioxidants.
    Kumar R; Ramachandran U; Srinivasan K; Ramarao P; Raichur S; Chakrabarti R
    Bioorg Med Chem; 2005 Jul; 13(13):4279-90. PubMed ID: 15869880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
    Devasthale PV; Chen S; Jeon Y; Qu F; Ryono DE; Wang W; Zhang H; Cheng L; Farrelly D; Golla R; Grover G; Ma Z; Moore L; Seethala R; Sun W; Doweyko AM; Chandrasena G; Sleph P; Hariharan N; Cheng PT
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2312-6. PubMed ID: 17292606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Almaden JV; Barnum SJ; Carlson TJ; Do QQ; Fraser JD; Hess M; Kim YH; Ogilvie KM; Sun S
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6116-9. PubMed ID: 16979341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Bailey S; Almaden JV; Barnum SJ; Carlson TJ; Christie LC; Do QQ; Fraser JD; Hess M; Kellum J; Kim YH; McClellan GA; Ogilvie KM; Simmons BH; Skalitzky D; Sun S; Wilhite D; Zehnder LR
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6120-3. PubMed ID: 16973358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CoMFA analysis of dual/multiple PPAR activators.
    Shah P; Mittal A; Bharatam PV
    Eur J Med Chem; 2008 Dec; 43(12):2784-91. PubMed ID: 18321611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.